Ira Winer, MD, PhD, assistant professor in the the Division of Gynecologic Oncology at Wayne State University, discusses the outlook on immunotherapy in the treatment landscape of gynecologic cancers.
Ira Winer, MD, PhD, assistant professor in the the Division of Gynecologic Oncology at Wayne State University, discusses the outlook on immunotherapy in the treatment landscape of gynecologic cancers.
At this point, everyone in the field understands that the immune system plays a big part in the treatment and reoccurrence of these diseases, Winer said. The key is to prevent cancers from returning, and if the immune system has such a large role in this, Winer expects that immunotherapy will become just as important in the treatment landscape as any other traditional therapy.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More